Celgene Corp

Latest Celgene Corp News and Updates

  • uploads///revenue EE
    Earnings Report

    How Vertex’s Revenue and Earnings Surprised in 2Q16

    Vertex Pharmaceuticals (VRTX) reported its 2Q16 earnings on July 27, 2016. VRTX surpassed Wall Street analysts’ projections and reported revenue of $431.6 million.

    By Jillian Dabney
  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned after 4Q17?

    In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    A Look at Ionis’s Revenue Streams in the Second Quarter

    Ionis Pharmaceuticals (IONS) reported year-over-year (or YoY) growth of 5% in revenues to $118 million during Q2 2018 as compared to the revenues of $112 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Celgene’s Revlimid Expected to Post Strong Revenue in 2017

    According to unaudited financial results published by Celgene (CELG) on January 9, 2017, Revlimid sales for 2016 are about $7.0 billion, a YoY rise of about 20.0%.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Alexion Pharmaceuticals Adds Metabolic Drug Kanuma to Portfolio

    Kanuma was acquired by Alexion Pharmaceuticals on completion of the acquisition of Synageva Pharmaceuticals in June 2015.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Must-Read: Amgen’s 3Q15 Earnings and Conference Call

    In its 3Q15 earnings report released on October 28, Amgen reported YoY revenue growth of ~14.0%, from $5.0 billion in 3Q14 to $5.7 billion in 3Q15.

    By Margaret Patrick
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Inside Celgene’s Revlimid: Strong Patient Demand in 4Q16

    After the approval of the drug as a therapy for newly diagnosed multiple myeloma, Celgene’s Revlimid has witnessed rapid growth in market share worldwide.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Analysts Expect Biogen’s Net Profit Margins to Rise in 3Q15

    Biogen’s (BIIB) 3Q15 earnings results will be announced on October 21, 2015. Analysts expect that the company will report lower net profit margins as compared to 2Q15.

    By Margaret Patrick
  • uploads///xtandi market share
    Company & Industry Overviews

    How Xtandi Fueled Big Pharmaceutical Interest in Medivation

    Xtandi is the major factor behind Pfizer’s (PFE) interest in Medivation (MDVN). The drug, along with MDVN’s pipeline molecules, should strengthen Pfizer’s (PFE) oncology franchise.

    By Jillian Dabney
  • Healthcare

    Third Point Partners ups stake in Amgen

    The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”

    By Samantha Nielson
  • uploads///Chart  CELG
    Company & Industry Overviews

    Celgene Stock Performance in 1Q18

    Wall Street analysts estimate that Celgene (CELG) stock has the potential to return 31.6% over the next 12 months.

    By Mike Benson
  • uploads///Part  Graph
    Company & Industry Overviews

    Allergan Boosts XLV Large-Caps with Positive 4Q15 Earnings

    Allergan (AGN) reported its 4Q15 earnings on February 22, 2016. It reported net revenue of $4.2 billion for 4Q15, an increase of 74% compared to $2.4 billion in 4Q14.

    By Peter Neil
  • uploads///AdobeStock_
    Fund Managers

    What Were the Top Holdings of Citadel Advisors in Q3?

    In Q3 2019, Citadel Advisors’ portfolio of publicly traded securities was worth $212.04 billion. In Q2 2019, its portfolio was worth $155.1 billion.

    By Rabindra Samanta
  • uploads///Revlimid revenue
    Company & Industry Overviews

    Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017

    In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

    By Daniel Collins
  • uploads///Graph
    Earnings Report

    Biogen Trades at High Valuation Multiples Due to Strong Research Pipeline

    After the release of its 3Q15 earnings results on October 21, Biogen was trading at PE multiples in the range of 13.8x–15.3x.

    By Margaret Patrick
  • uploads///HBbuysell
    Consumer

    Overview: Highbridge Capital Management’s 2Q14 positions

    Highbridge Capital Management is an alternative investment management organization. It was founded in 1992. The company has developed a diversified investment platform.

    By Patricia Garner
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Growth Rate and Estimates

    Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.

    By Mike Benson
  • uploads///Graph
    Earnings Report

    Behind Celgene’s Blockbuster Revenue Hit in 4Q16

    In 2016, Celgene’s (CELG) Otezla attained blockbuster status by earning revenues in excess of $1 billion as a therapy for psoriasis and psoriatic arthritis.

    By Margaret Patrick
  • uploads///AdobeStock_
    Consumer

    The George Soros Fund Shares 13F Analysis

    On November 14, The George Soros Fund Management LLC filed 13F. The firm’s total market value was around $3.6 billion at the end of Q3 2019.

    By Rabindra Samanta
  • uploads///Chart  Rev EPS
    Company & Industry Overviews

    What’s Gilead Sciences’ Valuation?

    Gilead’s stock price has risen ~8.9% in the last 12 months. Wall Street analysts estimate that the stock price will fall ~4.5% over the next 12 months.

    By Mike Benson
  • uploads///Kanuma
    Earnings Report

    How Kanuma’s Addition to Alexion’s Portfolio Impacts Its Earnings

    Alexion added Kanuma to its portfolio in 2015 after its Synageva acquisition. But ALXN didn’t have much time to build diagnostics as it did with Strensiq.

    By Jillian Dabney
  • uploads///Oncology
    Earnings Report

    AstraZeneca’s Oncology Segment: How Did It Perform in 2Q15?

    AstraZeneca’s oncology segment is another key focus area. The segment contributed 11.6% in 2014 and 12.1% in 2Q15. Key products for oncology are Zoladex and Faslodex.

    By Mike Benson
  • uploads///RD expenses Part
    Earnings Report

    How Much Does Biogen Spend on Research and Development?

    Biogen’s (BIIB) R&D expenses for 4Q15 were $542 million, or 19% of its total revenue, including a $60 million payment to Mitsubishi Tanabe.

    By Peter Neil
  • uploads///hospital _
    Earnings Report

    Allergan’s 1Q18 Earnings: Analysts’ Estimates

    Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

    By Mike Benson
  • uploads///Abraxane
    Company & Industry Overviews

    How’s Celgene’s Abraxane Positioned after 4Q17?

    In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///chemist _
    Healthcare

    Why Sesen Bio Stock Jumped Over 37% this Week

    Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Gilead Sciences’ Valuation Continues to Lag behind Peers

    Post 2014, Gilead Sciences has traded at lower valuation multiples, as investors are uncertain of the company’s ability to continue its leadership in the global HIV market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Do Analysts Recommend for AbbVie?

    Analysts updated their recommendations for AbbVie (ABBV) after the release of its 1Q16 earnings on April 28, 2016.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    What Biogen Is Doing that Put It in Good Favor with Analysts

    Based on recommendations from 25 broker companies, a Bloomberg survey reported that 62.5% of analysts gave Biogen (BIIB) “buy” recommendations.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Gilead Sciences in 4Q15: Analysts Project Modest Revenue Growth

    On February 02, 2016, Gilead Sciences will announce its 4Q15 earnings for the period ending December 31, 2015. Analysts expect modest revenue growth.

    By Margaret Patrick
  • uploads///Graph
    Earnings Report

    Celgene’s Operating Expenses in 3Q15

    In 3Q15, Celgene’s gross profit margin improved due to a favorable product mix composed mainly of Revlimid, Pomalyst, and Otezla.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inside AbbVie’s Analyst Recommendations in 2016

    Based on 24 recommendations, Bloomberg reported that 59.1% of analysts gave AbbVie a “buy” recommendation, while 36.4% of analysts gave the stock a “hold.”

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene Estimates Robust Revenue in 2017

    In 2017, Celgene (CELG) expects to earn revenues of $13.0 billion–$13.4 billion, which would be a YoY (year-over-year) growth of around 18.0%.

    By Margaret Patrick
  • uploads///aerial view of various medical pills pharmaceutical
    Company & Industry Overviews

    An Easier Way to Understand the Pharma Industry

    In 2018, the global pharmaceutical industry stood at $1.2 trillion, and experts expect $1.5 trillion by 2023. Here’s everything investors need to know.

    By Sybil Prowse
  • Healthcare

    Third Point believes Amgen’s acquisitions should have done more

    Faced with expiring patents and increasing competition for its blockbuster drugs, Amgen acquired Onyx to benefit from the latter’s innovative oncology portfolio and pipeline.

    By Samantha Nielson
  • uploads///stock trading monitor desk
    Consumer

    Renaissance Technologies: Analyzing Its Q3 13F

    At the end of the third quarter, Bristol-Myers Squibb, Celgene, Biogen, UnitedHealth, and Walmart (WMT) were Renaissance Technologies’ top five buys.

    By Rabindra Samanta
  • uploads///Graph
    Company & Industry Overviews

    AbbVie Expects Peak Sales of $7 Billion for Imbruvica

    AbbVie (ABBV) has projected Imbruvica’s annual revenues to be $5 billion by 2020. That would be driven by a rapid uptake in the first line chronic lymphocytic leukemia (or CLL) segment.

    By Margaret Patrick
  • uploads///AdobeStock_
    Energy & Utilities

    Analyzing Tudor Investment’s Top Holdings

    Tudor Investment founder Paul Tudor Jones II’s macro investment strategies have helped investors understand the opportunities in various securities.

    By Rabindra Samanta
  • uploads///AdobeStock_
    Company & Industry Overviews

    Amgen and Celgene’s Otezla Deal: Key Highlights

    On August 26, Amgen (AMGN) announced the purchase of leading immunology drug Otezla from Celgene (CELG) for a cash consideration of $13.4 billion.

    By Margaret Patrick
  • uploads///achievement _
    Company & Industry Overviews

    What’s the Latest on the BMY-Celgene Deal?

    Starboard Value has decided to give up the proxy war to stop Bristol-Myers Squibb’s deal with Celgene.

    By Margaret Patrick
  • uploads///merger _
    Healthcare

    Roche Holdings to Acquire Spark Therapeutics

    On February 25, Roche Holdings (RHHBY) issued a press release announcing that it has entered a definitive agreement to acquire Spark Therapeutics (ONCE).

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    ABBV or CELG: Comparing Dividends, Interest Expenses, and Debt

    AbbVie (ABBV) and Celgene (CELG) reported dividends per share of $3.59 and $0.0, respectively, in 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    AbbVie or Celgene: Which Is Expected to Report Faster EPS Growth?

    On its fourth-quarter earnings conference call, AbbVie (ABBV) guided for an adjusted gross margin of 82.5% in 2019.

    By Margaret Patrick
  • uploads///bacteria _
    Company & Industry Overviews

    What Analysts Recommend for AbbVie and Celgene This Month

    On February 5, AbbVie (ABBV) closed at $79.69, 1.48% higher than its previous closing price, 5.17% higher than its 52-week low of $75.77.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Celgene and Bristol-Myers Squibb’s Deal: What Are the Benefits?

    Bristol-Myers Squibb’s (BMY) acquisition of Celgene (CELG) will add the latter’s blockbuster multiple myeloma (or MM) drugs, Revlimid and Pomalyst, to the company’s portfolio.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    BMY and Celgene to Form a Leading Global BioPharma Company

    According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both solid tumor and hematologic malignancy segments.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Bristol-Myers Squibbs and Celgene: Cost Synergies for Future Years

    According to Bristol-Myers Squibb’s (BMY) press release, the company expects the acquisition of Celgene (CELG) to result in annual cost synergies close to $2.5 billion.

    By Margaret Patrick
  • uploads///BMYcelgene
    Company & Industry Overviews

    What to Expect from BMY’s Celgene Acquisition

    The acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) brings together both the company’s leading franchises.

    By Daniel Collins
  • uploads///pill _
    Company & Industry Overviews

    Bristol-Myers Squibb to Acquire Celgene

    Bristol-Myers Squibb has agreed to acquire Celgene in a cash and stock transaction valued at around $74.0 billion.

    By Daniel Collins
  • uploads///dna _
    Company & Industry Overviews

    Taking Stock of bluebird bio’s Performance

    In the third quarter, bluebird bio’s total revenue rose YoY (year-over-year) to $11.53 million from $7.71 million.

    By Kenneth Smith
  • uploads///Graph
    Company & Industry Overviews

    A Look at Abraxane’s Revenue Growth Trajectory in 2018

    In its third-quarter earnings conference call, Celgene (CELG) reiterated its expectation for Abraxane’s fiscal 2018 net product sales of around $1.0 billion.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    A Look at Celgene’s Revlimid Label Expansion Initiatives in 2018

    On October 23, 2018, Celgene issued a press release announcing favorable results from open-label Phase 2/3 trial, ECOG E3A06, evaluating Revlimid in the smoldering multiple myeloma (or MM) indication.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Inflammation and Immunology: Celgene’s Diversified Research Pipeline

    Celgene (CELG) is focused on advancing its diversified inflammation and immunology (or I&I) research pipeline in 2018.

    By Margaret Patrick
  • uploads///AstraZeneca
    Company & Industry Overviews

    Why Has AstraZeneca’s Stock Price Increased in 2018?

    On November 19, AstraZeneca’s (AZN) stock price closed at $40.80, which represents ~5% growth from its closing price of $38.78 on October 31.

    By Daniel Collins
  • uploads///capsule _
    Company & Industry Overviews

    How Wall Street Analysts View Merck

    On October 25, Merck (MRK) announced a dividend of $0.55 per share for its outstanding common stock in the fourth quarter of 2018.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Analysts Expect Incyte to Report Revenue Growth in Third Quarter

    Analysts estimate Incyte (INCY) to report growth of 17.7% in its revenues to $449.2 million during the third quarter of 2018.

    By Mike Benson
  • uploads///Oncology
    Company & Industry Overviews

    Johnson & Johnson’s Oncology Business Saw Solid Growth in Q3

    Johnson & Johnson’s (JNJ) oncology business generated revenue of $2.6 billion in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Earnings Report

    Biogen: Analysts’ Recommendations on October 19

    For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”

    By Mike Benson
  • uploads///revlimid
    Earnings Report

    Celgene: Multiple Myeloma Franchise Could Drive Growth

    In the multiple myeloma market, Celgene leads the immunomodulatory agent class of drugs with Revlimid, Pomalyst, and Thalomid.

    By Daniel Collins
  • uploads///capsule pill health medicine
    Company & Industry Overviews

    Celgene’s Financial Position before Its Third-Quarter Earnings

    Celgene is expected to report its third-quarter earnings on October 25. Celgene is expected to generate revenues of $3.8 billion in the third quarter.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Cara Therapeutics: Performance and Estimates for Q3

    Cara Therapeutics reported revenues of $2.87 million in the second quarter compared to no revenues in the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Stock Performance and Estimates for Q3 2018

    Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Revenue Stream

    Ionis’s Commercial Revenues segment reported second-quarter revenues of $57.0 million, compared to $24.0 million during the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Developments in September

    On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Here Are the Key Products in Sage’s GABA Receptor Portfolio

    Sage Therapeutics’ (SAGE) portfolio includes products under development for the treatment of life-threatening central nervous system (or CNS) disorders.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.

    By Mike Benson
  • uploads///medicine _
    Company & Industry Overviews

    Analyst Recommendations for Biogen and Its Peers in August

    On July 25, Biogen (BIIB) and Eisai announced positive results from the Phase 2 study evaluating BAN2401 in early Alzheimer’s disease.

    By Margaret Patrick
  • uploads///ALNY
    Earnings Report

    What Does Alnylam Pharmaceuticals’ Valuation Trend Indicate?

    In August, of the 16 analysts covering Alnylam Pharmaceuticals, 13 have given the stock “buy” or higher ratings.

    By Kenneth Smith
  • uploads///dna _
    Earnings Report

    What to Expect from Sarepta’s Second-Quarter Earnings

    Wall Street analysts estimate Sarepta’s revenues will increase by over 100% to $71.6 million in Q2 2018 as compared to revenues of $35.0 million during Q2 2017.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Bluebird Bio Stock

    As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.

    By Mike Benson
  • uploads///thermometer _
    Earnings Report

    Shire’s Q2 2018 Earnings Beat Analyst Estimates

    Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.

    By Mike Benson
  • uploads///syringe _
    Earnings Report

    Incyte’s Q2 2018 Earnings Beat Analysts’ Revenue Estimates

    Incyte (INCY) beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.27 on revenues of $521.5 million in Q2 2018.

    By Mike Benson
  • uploads///simone van der koelen  unsplash
    Earnings Report

    Merck Witnessed 5% Growth in Q2 2018

    Merck (MRK) generated revenues of $10.5 billion in the second quarter, reflecting ~5.0% year-over-year growth.

    By Daniel Collins
  • uploads///drug _
    Earnings Report

    Amgen Beats Estimates, Reports Growth in Q2 2018

    Amgen (AMGN) reported in Q2 2018 results yesterday, surpassing analysts’ EPS and revenue estimates.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Amgen Announced the Phase 3 Results for ABP 710

    On June 27, Amgen (AMGN) announced the top-line results for the NCT02937701 study—a Phase 3 study evaluating safety and efficacy of ABP 710.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why Editas Medicine Fell 7.8% on Monday

    On June 11, Editas Medicine (EDIT) stock fell 7.8% over concerns that CRISPR CAS-9 Gene Therapy causes cancer.

    By Mike Benson
  • uploads///hand _
    Company & Industry Overviews

    How Much Upside Potential Does Celgene Offer?

    Of the 30 analysts covering Celgene in May, 15 analysts rated the stock a “buy” or higher, and 14 analysts gave Celgene a “hold” rating.

    By Kenneth Smith
  • uploads///Celg
    Earnings Report

    How Celgene Performed in 1Q18

    In 1Q18, Celgene’s (CELG) revenue grew 20% year-over-year to $3.5 billion from $3.0 billion, boosted by Revlimid, Pomalyst, and Otezla sales.

    By Daniel Collins
  • uploads///office _
    Materials

    18 Earnings Reports We’re Watching Closely Next Week

    Last big week of earnings kicks off with not a lot to show for it in the market The week of April 30 is an exciting one in terms of earnings, and here are 18 companies we will be watching closely: Monday McDonald’s Corporation (NYSE: MCD) – before the market opens – great year last […]

    By JP Gravitt
  • uploads///pill _
    Healthcare

    Otezla: Shoring Up Celgene’s Top Line

    Celgene’s Otezla has been approved for the treatment of psoriatic arthritis and psoriasis in US, Japanese, EU, and other markets.

    By Kenneth Smith
  • uploads///test
    Company & Industry Overviews

    Gilead Sciences’ Valuation in March 2018

    Gilead Sciences surpassed analysts’ estimates and reported an EPS of $1.78 on revenues of $5.9 billion during 4Q17.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Kymriah May Emerge as a Robust Treatment Option in DLBCL Indication

    Kymriah is the first FDA-approved chimeric antigen receptor T cell (or CAR-T) therapy.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Novartis’ Kymriah: The First Gene Therapy to Be Approved in the US

    The National Cancer Institute estimates that the incidence of ALL in patients aged 20 or younger is ~3,100 in the US.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Imbruvica Leads in the Chronic Lymphocytic Leukemia Space

    AbbVie (ABBV) expects Imbruvica to contribute ~$3.3 billion in revenue in 2018, including $2.7 billion worth of sales contributions from the US market.

    By Margaret Patrick
  • uploads///PROPHYLAXIS
    Company & Industry Overviews

    Sanofi Leads the Hemophilia Space on Bioverativ Acquisition

    According to Sanofi’s (SNY) 2020 roadmap, the company is focused on sustaining a position of leadership in some of its key markets, including the rare diseases space.

    By Sarah Collins
  • uploads///bioverativ_businessprofile
    Company & Industry Overviews

    Exploring Bioverativ’s Business Profile and Market Presence

    Bioverativ completed its spin-off from Biogen (BIIB) in February 2017. Bioverativ is expected to register 30% growth in 2017.

    By Sarah Collins
  • uploads///Graph
    Company & Industry Overviews

    Humira Will Remain a Key Growth Driver for AbbVie in 2018

    AbbVie (ABBV) expects Humira to report year-over-year (or YoY) growth in its US market sales in the range of 13%–14% in 2018.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    GSK Is Focused on Innovative Assets in Oncology Research Pipeline

    In 2018, GlaxoSmithKline aims to initiate a pivotal phase 2 trial to evaluate GSK 916 as monotherapy Darzalex refractory population as the fourth line or the last line of multiple myeloma therapy.

    By Margaret Patrick
  • uploads///ATRA focus Therapies
    Company & Industry Overviews

    Inside Atara Biotherapeutics’ Promising Product Pipeline

    Atara’s most advanced T-cell therapy in development is its ATA129, which is under development for the treatment of cancer patients with Epstein Barr virus.

    By Kenneth Smith
  • uploads///Celgene
    Company & Industry Overviews

    Celgene on the Street: Analysts Recommendations in January

    In 1Q17, 2Q17, and 3Q17, Celgene (CELG) generated revenues of $2.96 billion, $3.27 billion, and $3.29 billion, respectively.

    By Daniel Collins
  • uploads///Celgene acquires
    Company & Industry Overviews

    Celgene to Acquire Juno Therapeutics

    On January 22, 2018, Celgene and Juno Therapeutics announced a merger agreement in which the former will acquire the latter’s business.

    By Daniel Collins
  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned for 2018?

    In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) Cosentyx generated revenues of $410 million, $490 million, and $556 million, respectively.

    By Daniel Collins
  • uploads///Crizan
    Company & Industry Overviews

    Novartis’s Crizanlizumab Demonstrates Positive Results in Trials

    In December 2017, Novartis presented the results from the post-hoc subgroup analysis of the phase 2 Sustain trial.

    By Daniel Collins
  • uploads///Kymriah Juliet
    Company & Industry Overviews

    Key Updates on Novartis’s Kymriah

    In December 2017, Novartis (NVS) presented updated results from the Juliet clinical trial, which demonstrated sustained responses of Kymriah (tisagenlecleucel) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (or DLBCL).

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Exploring Ionis’s 3Q17 Quarterly Revenue Trend

    Ionis’s revenue sources include its commercial revenue and its research and development revenue under its collaborative agreements.

    By Mike Benson
  • uploads///Perjeta
    Company & Industry Overviews

    Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018

    In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.

    By Daniel Collins
  • uploads///Graph
    Company & Industry Overviews

    Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications

    AbbVie (ABBV) is focused on expanding Risankizumab’s label for multiple indications such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why AbbVie Could See a Big Rise in Its Net Profit Margin in Fiscal 2017

    In its 3Q17 earnings conference call, AbbVie raised its fiscal 2017 adjusted diluted EPS (earnings per share) guidance from $5.44–$5.54 to $5.53–$5.55.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    How Increasing Biologic Penetration Could Boost AbbVie’s Revenues

    AbbVie (ABBV) is currently focused on advancing the research programs for its late-stage immunology assets, Upadacitinib and Risankizumab.

    By Margaret Patrick
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.